Overview Dividends

(VTR) Ventas - Ratings and Ratios

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US92276F1003

Senior Housing, Medical Buildings, Research Centers, Healthcare Facilities

EPS (Earnings per Share)

EPS (Earnings per Share) of VTR over the last years for every Quarter: "2020-09": 0.03, "2020-12": 0.29, "2021-03": -0.15, "2021-06": 0.23, "2021-09": 0.16, "2021-12": -0.1, "2022-03": 0.1, "2022-06": -0.11, "2022-09": 0.0031, "2022-12": -0.11, "2023-03": 0.04, "2023-06": 0.18, "2023-09": -0.18, "2023-12": -0.23, "2024-03": -0.03, "2024-06": 0.05, "2024-09": 0.05, "2024-12": 0.13, "2025-03": 0.1, "2025-06": 0.15, "2025-09": 0.121,
EPS CAGR: 44.58%
EPS Trend: 51.6%
Last SUE: 0.15σ
Qual. Beats: 0

Revenue

Revenue of VTR over the last years for every Quarter: 2020-09: 918.94, 2020-12: 921.165, 2021-03: 910.291, 2021-06: 919.194, 2021-09: 976.078, 2021-12: 1022.444, 2022-03: 1017.554, 2022-06: 1022.938, 2022-09: 1037.276, 2022-12: 1051.425, 2023-03: 1077.245, 2023-06: 1106.358, 2023-09: 1149.832, 2023-12: 1164.392, 2024-03: 1199.914, 2024-06: 1200.98, 2024-09: 1236.315, 2024-12: 1287.057, 2025-03: 1358.074, 2025-06: 1420.893, 2025-09: 1488.996,
Revenue CAGR: 13.49%
Revenue Trend: 98.2%
Last SUE: 3.72σ
Qual. Beats: 5
Risk via 10d forecast
Volatility 19.2%
Value at Risk 5%th 29.8%
Relative Tail Risk -5.63%
Reward TTM
Sharpe Ratio 0.96
Alpha 19.60
Character TTM
Hurst Exponent 0.295
Beta 0.266
Beta Downside 0.403
Drawdowns 3y
Max DD 22.88%
Mean DD 7.31%
Median DD 6.00%

Description: VTR Ventas October 14, 2025

Ventas, Inc. (NYSE: VTR) is a S&P 500-listed REIT focused on health-care real estate, operating roughly 1,400 properties across North America and the United Kingdom. Its core assets are more than 850 senior-housing communities, complemented by outpatient medical buildings, research centers, and other health-care facilities, positioning the company within the expanding “longevity economy.”

Key operational metrics show a FY 2023 occupancy rate of ~94% across senior-housing assets and a FY 2023 Funds-From-Operations (FFO) growth of 5% year-over-year, supporting a current dividend yield of about 5.5%. The portfolio’s performance is closely tied to macro drivers such as the U.S. aging demographic (projected to add ~10 million adults aged 65+ by 2030) and the prevailing interest-rate environment, which influences REIT cap rates and borrowing costs.

For investors seeking deeper quantitative insight, exploring ValueRay’s proprietary analytics on Ventas’ cash-flow sensitivity to interest-rate shifts can reveal hidden upside or downside scenarios worth further investigation.

VTR Stock Overview

Market Cap in USD 37,222m
Sub-Industry Health Care REITs
IPO / Inception 1998-05-04
Return 12m vs S&P 500 13.4%
Analyst Rating 4.45 of 5

VTR Dividends

Metric Value
Dividend Yield 2.40%
Yield on Cost 5y 4.70%
Yield CAGR 5y -4.27%
Payout Consistency 97.1%
Payout Ratio 3.8%

VTR Growth Ratios

Metric Value
CAGR 3y 24.70%
CAGR/Max DD Calmar Ratio 1.08
CAGR/Mean DD Pain Ratio 3.38
Current Volume 2441.3k
Average Volume 3006k

Piotroski VR‑10 (Strict, 0-10) 3.0

Net Income (238.0m TTM) > 0 and > 6% of Revenue (6% = 333.3m TTM)
FCFTA 0.04 (>2.0%) and ΔFCFTA 1.19pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue -8.89% (prev 6.51%; Δ -15.40pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA 0.06 (>3.0%) and CFO 1.55b > Net Income 238.0m (YES >=105%, WARN >=100%)
Net Debt (12.60b) to EBITDA (2.15b) ratio: 5.87 <= 3.0 (WARN <= 3.5)
Current Ratio 0.63 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (456.4m) change vs 12m ago 8.80% (target <= -2.0% for YES)
Gross Margin 41.97% (prev 42.61%; Δ -0.64pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 21.25% (prev 18.94%; Δ 2.31pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio 1.07 (EBITDA TTM 2.15b / Interest Expense TTM 752.5m) >= 6 (WARN >= 3)

Altman Z'' -1.87

(A) -0.02 = (Total Current Assets 849.3m - Total Current Liabilities 1.34b) / Total Assets 26.93b
(B) -0.27 = Retained Earnings (Balance) -7.37b / Total Assets 26.93b
(C) 0.03 = EBIT TTM 808.6m / Avg Total Assets 26.14b
(D) -1.01 = Book Value of Equity -14.66b / Total Liabilities 14.50b
Total Rating: -1.87 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 61.16

1. Piotroski 3.0pt
2. FCF Yield 2.31%
3. FCF Margin 20.74%
4. Debt/Equity 1.03
5. Debt/Ebitda 5.87
6. ROIC - WACC (= -2.23)%
7. RoE 2.06%
8. Rev. Trend 98.25%
9. EPS Trend 51.59%

What is the price of VTR shares?

As of November 26, 2025, the stock is trading at USD 78.80 with a total of 2,441,347 shares traded.
Over the past week, the price has changed by -0.25%, over one month by +11.95%, over three months by +17.17% and over the past year by +28.40%.

Is VTR a buy, sell or hold?

Ventas has received a consensus analysts rating of 4.45. Therefore, it is recommended to buy VTR.
  • Strong Buy: 12
  • Buy: 5
  • Hold: 3
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the VTR price?

Issuer Target Up/Down from current
Wallstreet Target Price 81.9 3.9%
Analysts Target Price 81.9 3.9%
ValueRay Target Price 91.7 16.3%

VTR Fundamental Data Overview November 25, 2025

Market Cap USD = 37.22b (37.22b USD * 1.0 USD.USD)
P/E Trailing = 149.5095
P/E Forward = 135.1351
P/S = 6.7138
P/B = 3.011
P/EG = 1.7374
Beta = 0.802
Revenue TTM = 5.56b USD
EBIT TTM = 808.6m USD
EBITDA TTM = 2.15b USD
Long Term Debt = 12.57b USD (from longTermDebt, last quarter)
Short Term Debt = 107.3m USD (from shortTermDebt, last quarter)
Debt = 12.79b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 12.60b USD (from netDebt column, last quarter)
Enterprise Value = 49.82b USD (37.22b + Debt 12.79b - CCE 188.6m)
Interest Coverage Ratio = 1.07 (Ebit TTM 808.6m / Interest Expense TTM 752.5m)
FCF Yield = 2.31% (FCF TTM 1.15b / Enterprise Value 49.82b)
FCF Margin = 20.74% (FCF TTM 1.15b / Revenue TTM 5.56b)
Net Margin = 4.28% (Net Income TTM 238.0m / Revenue TTM 5.56b)
Gross Margin = 41.97% ((Revenue TTM 5.56b - Cost of Revenue TTM 3.22b) / Revenue TTM)
Gross Margin QoQ = 41.58% (prev 41.80%)
Tobins Q-Ratio = 1.85 (Enterprise Value 49.82b / Total Assets 26.93b)
Interest Expense / Debt = 2.34% (Interest Expense 299.7m / Debt 12.79b)
Taxrate = -10.17% (negative due to tax credits) (-6.34m / 62.4m)
NOPAT = 890.9m (EBIT 808.6m * (1 - -10.17%)) [negative tax rate / tax credits]
Current Ratio = 0.63 (Total Current Assets 849.3m / Total Current Liabilities 1.34b)
Debt / Equity = 1.03 (Debt 12.79b / totalStockholderEquity, last quarter 12.36b)
Debt / EBITDA = 5.87 (Net Debt 12.60b / EBITDA 2.15b)
Debt / FCF = 10.93 (Net Debt 12.60b / FCF TTM 1.15b)
Total Stockholder Equity = 11.53b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.88% (Net Income 238.0m / Total Assets 26.93b)
RoE = 2.06% (Net Income TTM 238.0m / Total Stockholder Equity 11.53b)
RoCE = 3.35% (EBIT 808.6m / Capital Employed (Equity 11.53b + L.T.Debt 12.57b))
RoIC = 3.64% (NOPAT 890.9m / Invested Capital 24.50b)
WACC = 5.87% (E(37.22b)/V(50.01b) * Re(7.0%) + D(12.79b)/V(50.01b) * Rd(2.34%) * (1-Tc(-0.10)))
Discount Rate = 7.0% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 5.90%
[DCF Debug] Terminal Value 79.93% ; FCFE base≈1.00b ; Y1≈1.13b ; Y5≈1.52b
Fair Price DCF = 56.25 (DCF Value 26.42b / Shares Outstanding 469.7m; 5y FCF grow 14.74% → 3.0% )
EPS Correlation: 51.59 | EPS CAGR: 44.58% | SUE: 0.15 | # QB: 0
Revenue Correlation: 98.25 | Revenue CAGR: 13.49% | SUE: 3.72 | # QB: 5

Additional Sources for VTR Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle